What is Vetmedin-CA1?
VETMEDIN®-CA1 (pimobendan) chewable tablets is conditionally approved for the treatment of dogs with myxomatous mitral valve disease (MMVD) in the pre-clinical stage B2 (asymptomatic with a murmur/abnormal heart sounds and evidence of increased heart size) to delay onset of clinical signs of heart failure. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-556 (please see full prescribing information).
Given every 12 hours, the unique dual action of VETMEDIN®-CA1 dilates the blood vessels carrying blood to and from the heart—reducing the overall load on the heart—while simultaneously improving the ability of the heart muscle to contract.
The active ingredient in VETMEDIN®-CA1 (pimobendan) helps the heart muscle to contract and relax (pump) more effectively and it dilates blood vessels which reduces the amount of force with which the heart needs to pump blood.
- Recommended for dogs diagnosed with Stage B2 MMVD, VETMEDIN®-CA1 (pimobendan) can be used for the delay of onset of congestive heart failure.
- May prolong the number of symptom-free days in dogs.
- VETMEDIN®-CA1 helps dogs continue to engage in the daily activities they enjoy.
- Available as a beef-flavored, chewable tablet in 2 convenient dosing sizes (1.25 mg and 5 mg).
How does Vetmedin-CA1 work?
VETMEDIN-CA1 (pimobendan) is indicated for the delay of onset of congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease (2019 ACVIM Consensus Statement1 ).
Observe good industrial hygiene practices. Wash hands after handling.
Keep out of reach of children and pets. Store at 20 to 25°C (68° to 77°F). Store away from incompatible materials. Dispose of waste and residues in accordance with local authority requirements.
What is the most important thing I should know about Vetmedin-CA1?
For dogs with valvular insufficiency it extends life and improves quality of life.
What should I discuss with my veterinarian before giving Vetmedin-CA1 to my pet?
If there is a prescription for Vetmedin CA-1, there should be no questions. If there is no prescription, they should ask if their dog is a candidate for Vetmedin CA-1. VETMEDIN®-CA1 should be given to your dog once a veterinarian has confirmed that it meets the criteria for Stage B2 preclinical myxomatous mitral valve disease.
How should Vetmedin-CA1 be given ?
Give by mouth as prescribed.
What are the potential side effects of Vetmedin-CA1?
The most common side effects seen in dogs with Stage B2 MMVD while taking VETMEDIN®-CA1 Chewable Tablets are cough, vomiting, diarrhea, lethargy (lack of energy), and localized pain (such as in the neck or legs). If side effects occur, consult your veterinarian.
What happens if I miss giving a dose of Vetmedin-CA1?
If a dose of VETMEDIN®-CA1 is missed give the next scheduled dose at the normal time. There’s no need to give a higher dose.
What happens if I overdose my pet on Vetmedin-CA1?
Call your veterinarian.
What should I avoid while giving Vetmedin-CA1 to my pet?
Avoid leaving the bottle where the dog can access it. There are reported cases where dogs get into the bottle and eat all the tablets.
What other drugs will affect Vetmedin-CA1?
There are no known adverse drug interactions
- VETMEDIN-CA1 should be administered orally at a total daily dose of 0.23 mg/lb (0.5 mg/kg) body weight, using a suitable combination of whole or half tablets.
- The total daily dose should be divided into 2 portions that are not necessarily equal, and the portions should be administered approximately 12 hours apart (i.e., morning and evening).
The tablets are scored, and the calculated dosage should be provided to the nearest half tablet increment
|All weights||.23mg per 1lb body weight|
|Cats||Do not use!|
|Horses||Do not use!|
|Active Ingredients: pimobendan|